VICO.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:29):

Stats
Today's Volume	149 676
Average Volume	207 556
Market Cap	1.86B
EPS	SEK0 ( 2024-02-28 )
Next earnings date	( SEK0 ) 2024-05-03
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-5.18
ATR14	SEK0.0460 (0.28%)

Volume Correlation

Long: -0.04 (neutral)

Short: -0.65 (weak negative)

Signal:(48.549) Neutral

Vicore Pharma Holding AB Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vicore Pharma Holding AB Correlation - Currency/Commodity

0.04
( neutral )

0.70
( moderate )

0.00
( neutral )

-0.91
( very strong negative )

0.58
( weak )

0.68
( moderate )

Vicore Pharma Holding AB Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-3.42M (0.00 %)
EPS:	SEK-3.22

Q4	2023
Revenue:	SEK0
Gross Profit:	SEK-51.39M (0.00 %)
EPS:	SEK-1.000

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-840 000 (0.00 %)
EPS:	SEK-0.580

Q2	2023
Revenue:	SEK0
Gross Profit:	SEK-839 000 (0.00 %)
EPS:	SEK-0.850

Financial Reports:

No articles found.

Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.